Guggenheim Reiterates Buy on Outlook Therapeutics, Maintains $12 Price Target

Benzinga · 01/17 14:16
Guggenheim analyst Eddie Hickman reiterates Outlook Therapeutics (NASDAQ:OTLK) with a Buy and maintains $12 price target.